Mod­er­na spells out rare dis­ease am­bi­tions: 'We have a bunch of INDs planned'

Mod­er­na said in June that it was “qua­dru­pling down” on rare dis­ease. Right now, that looks like nine or so INDs in the plan­ning phase and po­ten­tial­ly “many more com­ing af­ter,” ac­cord­ing to head of de­vel­op­ment for ther­a­peu­tics and on­col­o­gy Kyle Holen.

The pub­lic fo­cus at Mod­er­na has been trained on RSV and the chal­lenges of shift­ing out of a pan­dem­ic mar­ket for Covid-19. The com­pa­ny has re­peat­ed­ly said there’s much more it wants to do with mR­NA be­yond vac­cines, in­clud­ing us­ing it to sup­ply the ge­net­ic code for miss­ing or bro­ken pro­teins that dri­ve rare dis­ease. But ex­ec­u­tives have kept their cards rel­a­tive­ly close.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER